Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Recruiting

Study on the Effects of MORF-057 for Adults with Moderate to Severe Crohn's Disease

Verified siteInvestigational
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the effects of a new treatment for Crohn's Disease, a condition that causes inflammation in the digestive tract, leading to symptoms like abdominal pain and diarrhea. The treatment being tested is called MORF-057, which is taken in the form of a capsule. The study will compare the effects of two different doses of MORF-057 to a placebo, which looks like the treatment but does not contain the active medicine.

The purpose of the study is to evaluate the safety and effectiveness of MORF-057 in adults with moderately to severely active Crohn's Disease. Participants will be randomly assigned to receive either MORF-057 or a placebo. The study will last for several weeks, during which participants will take the capsules and attend regular check-ups to monitor their health and the effects of the treatment.

Throughout the study, doctors will use a method called endoscopy to look inside the digestive tract and assess how well the treatment is working. The main goal is to see if MORF-057 can help reduce the inflammation and improve symptoms by the end of the study period. Participants will also be monitored for any side effects or changes in their health to ensure the treatment is safe.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial assessment

    Upon joining the study, an initial assessment is conducted to confirm eligibility. This includes reviewing medical history and current health status.

    The assessment ensures that the participant has moderately to severely active Crohn's disease, confirmed by specific scores from medical evaluations.

  2. Step 2

    Treatment allocation

    Participants are randomly assigned to receive either the active medication, MORF-057, or a placebo. The study is double-blind, meaning neither the participant nor the study team knows which treatment is being administered.

    The medication is provided in capsule form for oral use.

  3. Step 3

    Medication administration

    Participants take the assigned capsule daily. The dosage and specific regimen are determined by the study protocol.

    The treatment period lasts for 14 weeks, during which the participant's response to the medication is closely monitored.

  4. Step 4

    Monitoring and assessments

    Regular assessments are conducted to monitor the participant's health and response to the treatment. This includes checking for any side effects and evaluating the effectiveness of the medication.

    Endoscopic evaluations are performed to assess the condition of the intestines at the end of the 14-week period.

  5. Step 5

    Final evaluation

    At the end of the treatment period, a final evaluation is conducted to determine the participant's response to the treatment.

    The primary goal is to assess the proportion of participants who show an endoscopic response, indicating improvement in the condition.

Who can join the trial?

12 criteria

  • Must be a male or female between 18 to 85 years old.
  • Must have been diagnosed with **Crohn's Disease (CD)** for at least 3 months. This diagnosis should be supported by symptoms, an endoscopy (a procedure to look inside the digestive tract), and a biopsy (a small tissue sample).
  • Must have **moderately to severely active Crohn's Disease**, confirmed by specific scores during the screening period.
  • Must have an average daily stool score of 4 or more points and/or an average daily abdominal pain score of 2 or more points.
  • Must have shown an inadequate response, loss of response, or intolerance to at least one treatment for Crohn's Disease, such as corticosteroids, immunosuppressants, or advanced therapies.
  • Must meet specific washout criteria for previous Crohn's Disease therapies, meaning certain medications must be stopped for a specific time before starting the study.
  • If taking certain non-prohibited medications for Crohn's Disease, must stop them at least 5 half-lives before the study or agree to maintain stable doses, except for tapering oral corticosteroids after the induction period.
  • Must have a **body mass index (BMI)** of 18.0 or higher. BMI is a measure of body fat based on height and weight.
  • Must be able to fully participate in all aspects of the study, as determined by the investigator.
  • Must agree to follow guidelines regarding contraception. This includes using effective birth control methods or abstaining from sexual intercourse during the study and for a specified time after the last dose of the study medication.
  • Must agree not to donate sperm or eggs during the study and for a specified time after the last dose of the study medication.
  • Must be capable of giving signed informed consent, which means understanding and agreeing to the study's requirements and restrictions.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

RecruitingNot recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

MORF-057 is a medication being studied for its potential to help people with moderately to severely active Crohn's Disease. The trial aims to see how well this medication works in reducing inflammation in the intestines, which is checked through a procedure called an endoscopy. The study will assess the effects of this medication over a period of 14 weeks to determine its safety and effectiveness in improving the symptoms of Crohn's Disease.

What is already known about the treatment

MORF-057 – MORF-057 is administered orally and is currently being studied in clinical trials for its potential use in treating moderately to severely active Crohn's Disease. It is in the Phase 2 stage of clinical trials, where its safety and efficacy are being evaluated. The main therapeutic indication for MORF-057 is to reduce inflammation and improve symptoms in patients with Crohn's Disease. At the molecular level, MORF-057 works by modulating specific pathways involved in the inflammatory process, aiming to achieve an endoscopic response. It is classified pharmacologically as an anti-inflammatory agent.

Investigated diseases

Crohn's Disease – Crohn's Disease is a chronic inflammatory condition of the gastrointestinal tract, primarily affecting the small intestine and colon. It is characterized by periods of active symptoms and remission. During active phases, individuals may experience abdominal pain, diarrhea, fatigue, and weight loss. The inflammation can lead to complications such as strictures or fistulas. The exact cause is unknown, but it involves an abnormal immune response. The disease can vary greatly in severity and progression among individuals.
Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase IITrial ID2023-508158-24-00Protocol codeMORF-057-203Estimated enrolment395 patientsSponsorMorphic Therapeutic Inc.

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.